Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune, Antiviral, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IFNLR1/IL28RA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IFNLR1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View IFNLR1 Products |
| Gene Delivery | IFNLR1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and signaling assays. |
View IFNLR1 Products |
| Benchmark Ab | Anti-IFNLR1 Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark clones. |
View IFNLR1 Products |
| Validator | IFNLR1 siRNA Set Target-specific knockdown verification in functional cell assays. |
View IFNLR1 Products |
| Related Target A | IL10RB Required heterodimeric partner for IFNLR1 signaling activation. |
View IL10RB Products |
| Related Target B | IFNL1 (IL29) High-affinity endogenous ligand for the IFNLR1/IL10RB receptor complex. |
View IFNL1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ligand-Receptor Blocking Verification | HEK293-expressed IFNLR1 and IL10RB with native glycosylation patterns to preserve physiological binding epitopes. |
| Cross-species Reactivity Profiling | Human, Mouse, and Cynomolgus IFNLR1 ortholog proteins available with sequence verification and high purity (>95%). |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration and comparative screening. |
| False Positives | Validated siRNA included for specificity and target-knockdown verification in reporter assays. |
Live IFNLR1/IL28RA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IFNLR1/IL28RA therapeutics is intensifying, with major players shifting focus from traditional recombinant ligands to highly targeted monoclonal antibodies and bispecific formats. Because the interferon lambda receptor complex (composed of IFNLR1 and IL10RB) is primarily expressed on epithelial cells, targeting this pathway offers a unique anatomical compartmentalization. This localized signaling avoids the systemic, pro-inflammatory toxicities associated with Type I Interferons (IFN-alpha/beta) while maintaining robust antiviral and mucosal barrier protection.
As first-generation pegylated interferon-lambdas reach late-stage clinical evaluation, the next wave of R&D is targeting chronic inflammatory and autoimmune disorders, such as Systemic Lupus Erythematosus (SLE) and Inflammatory Bowel Disease (IBD), where overactivation of the IFN-lambda pathway drives pathology. Consequently, blocking antibodies targeting IFNLR1 are entering the clinic to suppress chronic epithelial inflammation without compromising systemic immune homeostasis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Blocking mAb | Bristol Myers Squibb, AstraZeneca | Systemic Lupus Erythematosus (SLE), Lupus Nephritis, IBD | Epitope mapping & ligand blocking (Needs high-purity, natively glycosylated IFNLR1 ECD-Fc) |
| Agonist Recombinant Proteins | Eiger BioPharmaceuticals, Shanghai Roche | Hepatitis D (HDV), COVID-19, Viral Infections | Receptor complex assembly validation (Needs IFNLR1 & IL10RB heterodimerization assays) |
| Bispecific / Cytokine Fusions | Academic & Biotech Consortia | Solid Tumors (Epithelial-derived) | Selectivity and affinity profiling (Needs high-purity mutant and wild-type receptor panels) |